Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.8268
-0.0128-1.52%
Post-market: 0.82690.0001+0.01%19:39 EDT
Volume:1.17M
Turnover:952.73K
Market Cap:69.83M
PE:-0.28
High:0.8530
Open:0.8225
Low:0.8003
Close:0.8396
Loading ...
May 07, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2021

Major Issues Report

8-K - Current report
Apr 15, 2021

Major Issues Report

8-K - Current report
Apr 05, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Mar 18, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 18, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 18, 2021

Major Issues Report

8-K - Current report
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 09, 2020

Major Issues Report

8-K - Current report
Dec 07, 2020

Major Issues Report

8-K - Current report
Dec 04, 2020

Major Issues Report

8-K - Current report
Dec 01, 2020

Major Issues Report

8-K - Current report
Nov 05, 2020

Major Issues Report

8-K - Current report
Nov 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]